1. Home
  2. PSO vs CYTK Comparison

PSO vs CYTK Comparison

Compare PSO & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pearson Plc

PSO

Pearson Plc

N/A

Current Price

$13.05

Market Cap

8.2B

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$59.89

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSO
CYTK
Founded
1844
1997
Country
United Kingdom
United States
Employees
17116
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
7.6B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
PSO
CYTK
Price
$13.05
$59.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
18
Target Price
N/A
$87.56
AVG Volume (30 Days)
994.3K
1.7M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$5.90
$9.79
Revenue Next Year
$4.88
$302.66
P/E Ratio
$14.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.02
$29.31
52 Week High
$16.70
$70.98

Technical Indicators

Market Signals
Indicator
PSO
CYTK
Relative Strength Index (RSI) 53.58 40.30
Support Level $12.92 $59.25
Resistance Level $13.34 $65.93
Average True Range (ATR) 0.23 2.65
MACD 0.06 -0.32
Stochastic Oscillator 68.24 3.98

Price Performance

Historical Comparison
PSO
CYTK

About PSO Pearson Plc

UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: